# Implementing Fragmentomics Into Real World Screening IntervenTions to Evaluate Clinical Utility Among Individuals With Elevated Risk for Lung Cancer

> **NCT06145750** · NA · COMPLETED · sponsor: **Delfi Diagnostics Inc.** · enrollment: 28 (actual)

## Conditions studied

- Lung Cancer

## Interventions

- **DIAGNOSTIC_TEST:** Ability to order FirstLook™
- **OTHER:** Continuing Medical Education for Lung Cancer

## Key facts

- **NCT ID:** NCT06145750
- **Lead sponsor:** Delfi Diagnostics Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-10-31
- **Primary completion:** 2025-08-31
- **Final completion:** 2025-08-31
- **Target enrollment:** 28 (ACTUAL)
- **Last updated:** 2025-11-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06145750

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06145750, "Implementing Fragmentomics Into Real World Screening IntervenTions to Evaluate Clinical Utility Among Individuals With Elevated Risk for Lung Cancer". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT06145750. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*